SCHEMBL13509690

SCHEMBL13509690

Cc1ccc(C)c(S(=O)(=O)Nc2cc(Sc3ccccc3)c(O)c3ccccc23)c1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HKDC1 Q2TB90 5/20 0.72
▸ MEN1 O00255 4/20 0.72
▸ KMT2A Q03164 4/20 0.72
▸ MCL1 Q07820 4/20 0.72
▸ ALDH1A1 P00352 2/20 0.72
▸ LMNA P02545 2/20 0.72
▸ MAPT P10636 2/20 0.72
▸ HPGD P15428 2/20 0.72
▸ BLM P54132 2/20 0.72
▸ SMN1; SMN2 Q16637 2/20 0.72
▸ KDM4C Q9H3R0 2/20 0.72
▸ L3MBTL1 Q9Y468 2/20 0.72
▸ POLB P06746 1/20 0.72
▸ THRB P10828 1/20 0.72
▸ FSCN1 Q16658 3/20 0.69
▸ STAT3 P40763 1/20 0.62
▸ G6PD P11413 2/20 0.61
▸ GAA P10253 1/20 0.61
▸ BRAF P15056 1/20 0.60
▸ KDM4E B2RXH2 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13509689 0.91 FSCN1 (0.69) HKDC1MEN1KMT2AMCL1ALDH1A1
SCHEMBL15871900 0.90 STAT3 (0.66) HKDC1MEN1KMT2AMCL1ALDH1A1
SCHEMBL13509741 0.89 STAT3 (0.60) HKDC1MEN1KMT2AMCL1ALDH1A1
SCHEMBL13509730 0.87 STAT3 (0.58) HKDC1MEN1KMT2AMCL1ALDH1A1
SCHEMBL13509701 0.86 STAT3 (0.56) HKDC1MEN1KMT2AMCL1ALDH1A1
SCHEMBL13509685 0.85 MCL1 (0.71) HKDC1MEN1KMT2AMCL1ALDH1A1
SCHEMBL13509713 0.84 STAT3 (0.62) HKDC1MEN1KMT2AMCL1ALDH1A1
SCHEMBL15871909 0.83 STAT3 (0.64) HKDC1MEN1KMT2AMCL1ALDH1A1
SCHEMBL13509719 0.83 STAT3 (0.64) HKDC1MEN1KMT2AMCL1ALDH1A1
SCHEMBL15521868 0.83 FSCN1 (0.69) HKDC1MEN1KMT2AMCL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11161831-B2 Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia BAYLOR COLLEGE OF MEDICINE (US) 2021-11-02 — — US disclosed
WO-2021113551-A1 THERAPEUTIC COMPOUNDS FOR METHODS OF USE IN INSULIN RESISTANCE BAYLOR COLLEGE OF MEDICINE (US) 2021-06-10 — — WO disclosed
US-20200331880-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCLE WASTING, MUSCLE WEAKNESS, AND/OR CACHEXIA BAYLOR COLLEGE OF MEDICINE 2020-10-22 — — US disclosed
US-10676455-B2 Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia BAYLOR COLLEGE OF MEDICINE (US) 2020-06-09 — — US disclosed
US-20150051233-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF FIBROSIS BAYLOR COLLEGE OF MEDICINE 2015-02-19 — — US disclosed
US-20150051233-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF FIBROSIS BAYLOR COLLEGE OF MEDICINE 2015-02-19 — — US disclosed
US-20150031714-A1 METHODS AND COMPOSITIONS FOR PREVENTION OF ALLERGIC REACTION BAYLOR COLLEGE OF MEDICINE 2015-01-29 — — US disclosed
US-20150031714-A1 METHODS AND COMPOSITIONS FOR PREVENTION OF ALLERGIC REACTION BAYLOR COLLEGE OF MEDICINE 2015-01-29 — — US disclosed
US-20150024032-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCLE WASTING, MUSCLE WEAKNESS, AND/OR CACHEXIA BAYLOR COLLEGE OF MEDICINE 2015-01-22 — — US disclosed
US-20150024032-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCLE WASTING, MUSCLE WEAKNESS, AND/OR CACHEXIA BAYLOR COLLEGE OF MEDICINE 2015-01-22 — — US disclosed
US-20140296270-A1 STAT3 Inhibitors BAYLOR COLLEGE OF MEDICINE (US) 2014-10-02 — — US disclosed
US-20140296270-A1 STAT3 Inhibitors BAYLOR COLLEGE OF MEDICINE (US) 2014-10-02 — — US disclosed
US-8779001-B2 Stat3 inhibitors The United States of America National Institute of Health (NIH) (US) 2014-07-15 — — US disclosed
US-8779001-B2 Stat3 inhibitors The United States of America National Institute of Health (NIH) (US) 2014-07-15 — — US disclosed
US-20110312984-A1 STAT3 INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2011-12-22 — — US disclosed
US-20110312984-A1 STAT3 INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2011-12-22 — — US disclosed
US-20100041685-A1 STAT3 INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2010-02-18 — — US disclosed
US-20100041685-A1 STAT3 INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2010-02-18 — — US disclosed
WO-2009149192-A1 STAT3 INHIBITORS BAYLOR COLLEGE OF MEDICINE (US) 2009-12-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150051233-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF FIBROSIS STAT3, MMP1, MMP8 HKDC1 2208/4885MEN1 4463/4885KMT2A 2075/4885
US-10676455-B2 Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia PYGM, MYLK2, STAT3 HKDC1 1925/4885MEN1 4666/4885KMT2A 1055/4885
US-11161831-B2 Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia PYGM, MYLK2, STAT3 HKDC1 1925/4885MEN1 4666/4885KMT2A 1055/4885
US-20150024032-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCLE WASTING, MUSCLE WEAKNESS, AND/OR CACHEXIA PYGM, MYLK2, STAT3 HKDC1 1925/4885MEN1 4666/4885KMT2A 1055/4885
US-20100041685-A1 STAT3 INHIBITORS STAT3, STAT1, JAK2 HKDC1 3473/4885MEN1 3720/4885KMT2A 1456/4885
US-20200331880-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCLE WASTING, MUSCLE WEAKNESS, AND/OR CACHEXIA PYGM, MYLK2, STAT3 HKDC1 1925/4885MEN1 4666/4885KMT2A 1055/4885
US-20140296270-A1 STAT3 Inhibitors STAT3, STAT1, JAK2 HKDC1 3473/4885MEN1 3720/4885KMT2A 1456/4885
US-20150031714-A1 METHODS AND COMPOSITIONS FOR PREVENTION OF ALLERGIC REACTION JAK2, STAT3, STAT6 HKDC1 4538/4885MEN1 4165/4885KMT2A 527/4885
US-20110312984-A1 STAT3 INHIBITORS STAT3, STAT1, JAK2 HKDC1 3473/4885MEN1 3720/4885KMT2A 1456/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback